Early glycaemic changes after initiation of oral antidiabetic medication and risk of major adverse cardiovascular events: results from a large primary care population of patients with type 2 diabetes.
Jonas GhousePaul F BlancheMorten W SkovBent LindAllan VaagJørgen K KantersJesper H SvendsenLars KøberMorten S OlesenThomas A GerdsAnders G HolstJonas Bille NielsenPublished in: European heart journal. Cardiovascular pharmacotherapy (2022)
A combination of a high pre-treatment HbA1C and a steep decline in HbA1C was associated with a decreased short-term risk of MACE. A low pre-treatment HbA1C and a steep decline was associated with a long-term reduced risk of MACE, but a short-term increased risk of death and hypoglycaemia.